Combination therapy of hybrid cells with BCG injection for treating Cancer Patients
The present invention relates to cancer treatment compositions and methods for a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation in combination with Mycobacterium bovis bacillus Calmette-Guerin (BCG).
1 . A method for treating a patient with cancer comprising co-administering to a patient in need thereof a composition comprising a primary tumor cell fused to a dendritic cell, and Mycobacterium bovis bacillus Calmette-Guerin (BCG), wherein the BCG is not mixed with the hybrid cell composition.
2 . The method of claim 1 , wherein the BCG is not mixed with the hybrid cell composition.
3 . The method of claim 1 , wherein the patient has stage I, stage II, stage III, or stage IV cancer, wherein the cancer is according to the American Joint Committee on Cancer (AJCC) 2002 Staging System.
4 . The method of claim 3 , wherein the patient has stage IV cancer.
5 . The method of claim 3 , wherein the patient has a cancer selected from the group consisting of renal cancer, ovarian cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, skin cancer and neuroblastoma.
6 . The method of claim 5 , wherein the patient has neuroblastoma.
7 . The method of claim 1 , wherein the patient has no evidence of disease following surgery, radiation, chemotherapy, or a combination thereof.
8 . The method of claim 1 , wherein BCG is administered to the patient after administration of the hybrid cell composition.
9 . The method of claim 8 , wherein BCG is administered to the patient within about 10 minutes of the administration of the hybrid cell composition.
10 . A method for increasing survival of a patient with cancer, comprising co-administering to a patient in need thereof a composition compris a primary tumor cell fused to a dendritic cell, and Mycobacterium bovis bacillus Calmette-Guerin (BCG),
11 . The method of claim 10 , wherein the BCG is not mixed with the hybrid cell composition.
12 . The method of claim 11 , wherein the patient has stage IV cancer.
13 . The method of claim 11 , wherein the patient has a cancer selected from the group consisting of renal cancer, ovarian cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, skin cancer and neuroblastoma.
14 . The method of claim 13 , wherein the patient has neuroblastoma.
15 . The method of claim 13 , wherein the patient has no evidence of disease following surgery, radiation, chemotherapy, or a combination thereof.
16 . The method of claim 10 , wherein BCG is administered to the patient after administration of the hybrid cell composition.
17 . The method of claim 16 , wherein BCG is administered to the patient within about 10 minutes of the administration of the hybrid cell composition.
18 . A method for stimulating an immune response in a patient with cancer, comprising co-administering to a patient in need thereof a composition compris a primary tumor cell fused to a dendritic cell, and Mycobacterium bovis bacillus Calmette-Guerin (BCG), wherein the BCG is not mixed with the hybrid cell composition.
19 . The method of claim 18 , wherein the patient has stage IV cancer.
20 . The method of claim 18 , wherein the patient has a cancer selected from the group consisting of renal cancer, ovarian cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, skin cancer and neuroblastoma.
21 . The method of claim 20 , wherein the patient has neuroblastoma.
22 . The method of claim 20 , wherein the patient has no evidence of disease following surgery, radiation, chemotherapy, or a combination thereof.
23 . The method of claim 18 , wherein BCG is administered to the patient after administration of the hybrid cell composition.
24 . The method of claim 23 , wherein BCG is administered to the patient within about 10 minutes of the administration of the hybrid cell composition.